The combined pill clears acne, and the brand matters less than you'd think

Acne is one of the most common skin disorders among women, and there is no single agreed way to manage it. Combined oral contraceptives, which pair an oestrogen with a progestin, are frequently prescribed for acne, yet frequency of prescription is not the same as proof of effect. Women choosing between contraceptive options, or weighing whether the pill might help their skin, deserve to know whether the trial evidence backs the practice. This Cochrane review set out to establish whether combined pills genuinely improve facial acne compared with placebo or other therapies, and whether particular formulations work better than others.

The reviewers searched multiple databases including the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, POPLINE and LILACS, as well as trial registries, and wrote to trial authors to hunt down unpublished work. Any randomised controlled trial in any language comparing a combined oral contraceptive against placebo or another active acne therapy in women was eligible. They extracted data on total and specific facial lesion counts, acne severity grades, global assessments by clinicians and participants, and discontinuation due to adverse events. The search yielded 25 trials: 7 placebo-controlled trials making 4 different comparisons, 17 trials comparing different pill regimens across 13 comparisons, and 1 trial comparing a pill to an antibiotic.

Against placebo, combined oral contraceptives reduced acne lesion counts, severity grades and women's own assessments of their acne, covering both inflammatory and non-inflammatory lesions. The picture between pill types was far murkier. Pills containing chlormadinone acetate or cyproterone acetate appeared to improve acne more than levonorgestrel, though this apparent advantage rested on limited data. A cyproterone acetate pill might beat one containing desogestrel, but the three studies making that comparison produced conflicting results, and levonorgestrel versus desogestrel likewise split, with one trial favouring levonorgestrel slightly and a second finding the groups similar.

This review turns a widespread prescribing habit into an evidence-backed one, at least for the four pill types tested against placebo. It also punctures the idea that any particular formulation is clearly superior for skin, since head-to-head comparisons were thin and inconsistent. The biggest gap the reviewers flag is that almost no data existed comparing the pill against alternative acne treatments, so its place in the wider acne toolkit could not be judged. The review has since been updated, which is the normal life cycle of Cochrane evidence.

For women considering contraception who also deal with acne, this is a reason to think the combined pill can offer a genuine skin benefit alongside its primary purpose. It is equally a reason to be sceptical of claims that one branded pill is the acne pill, because the between-pill evidence was limited and contradictory. The review cannot tell you whether a pill would beat a dedicated acne treatment, since that comparison was barely studied. As ever with prescription medicine, the trade-offs are individual and belong in a conversation with a clinician.